ENLV stock forecast, quote, news & analysis
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis... Show more
Why Enlivex Ltd. (ENLV) Stock Is Down 77% in the Last 30 Days
Key Takeaways
- Enlivex Ltd. (ENLV) shares have declined roughly 77% over the past 30 days, extending a prolonged multi-month selloff.
- The decline reflects heavy selling pressure tied to a major restructuring and persistent cash-burn concerns at the pre-revenue, clinical-stage company.
- On October 19, 2026, Enlivex announced a cost-reduction plan that includes cutting its workforce by approximately 60% and winding down non-clinical R&D.
- The company is concentrating its remaining resources on the Phase 2b trial of Allocetra in age-related knee osteoarthritis, with topline six-month data expected by mid-2027.
- Enlivex holds FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra and reported positive Phase 1/2a results in the responder population.
- Over the last quarter the stock has fallen approximately 96%, indicating a broad de-rating rather than a single-day event.
- For more detail, explore ENLV's Price Targets, Earnings, and Forecast pages.
- Explore Tickeron's Trending AI Robots to see AI-driven trading strategies across thousands of tickers.
Enlivex Ltd. (ENLV) Company Overview and Market Position
Enlivex Ltd. (NASDAQ: ENLV) is an Israel-based, clinical-stage macrophage reprogramming immunotherapy company headquartered in Ness Ziona. Formerly known as Enlivex Therapeutics Ltd., the company changed its name to Enlivex Ltd. in February 2026. Its lead asset, Allocetra, is an off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.
The company's current clinical focus is age-related knee osteoarthritis. Allocetra is being evaluated in a global, multicenter, randomized, double-blind, placebo-controlled Phase 2b trial in patients aged 64 and older with moderate-to-severe age-related symptomatic primary knee osteoarthritis. In July 2026, the U.S. Food and Drug Administration granted RMAT designation for Allocetra in this indication, building on Phase 1/2a results that showed statistically significant improvements in knee pain and function versus placebo in the responder population.
In addition to its clinical programs, Enlivex describes itself as a "quality longevity company powered by a prediction markets treasury," operating a treasury strategy built around the Rain protocol, a decentralized prediction markets platform. Investors follow the stock primarily for its binary clinical milestones in the large osteoarthritis market, which affects more than 32 million Americans.
Enlivex Ltd. (ENLV) Stock Price Performance: Last 30 Days vs. Quarter
Enlivex shares have undergone a severe de-rating over the trailing 30 days. From a closing level of roughly $6.20 about a month earlier, the stock has fallen to approximately $1.42 in recent trading, a decline of roughly 77%.
The quarterly picture is even steeper. Around three months prior, ENLV traded near $34.72; the decline to the current level represents a drop of approximately 96%. The pattern has been characterized by a persistent downtrend with limited sustained rebounds, punctuated by elevated volume on down days, rather than a single isolated gap lower.
What Drove ENLV Stock Price in the Last 30 Days
The most significant verified catalyst was Enlivex's October 19, 2026 announcement of a cost-reduction plan. The company disclosed that it would reduce its workforce by approximately 60%, wind down all research and development activities unrelated to the Phase 2b Allocetra trial, cut management salaries by 20%, and reduce the Chief Executive Officer's salary by 40%. Management framed the plan as a way to substantially reduce cash burn and extend the company's runway to the mid-2027 data readout.
While intended to preserve capital, the restructuring was widely interpreted by the market as a signal of financial pressure at a pre-revenue company with limited cash generation. Selling pressure was further compounded by concerns about the company's unorthodox dual strategy combining a clinical-stage immunotherapy program with a prediction markets treasury, an approach that has contributed to elevated uncertainty among investors. The lack of near-term revenue, ongoing cash burn, and the extended timeline to the next major data catalyst all weighed on sentiment.
What Drove ENLV Stock Performance Over the Last Quarter
Over the trailing quarter, ENLV's decline reflects a broader, multi-month re-rating that began well before the October restructuring announcement. The stock has steadily retreated from substantially higher levels as investors reassessed the company's business model, cash position, and path to value creation.
The company's repositioning toward a hybrid model—developing Allocetra while operating a prediction markets treasury—introduced new risk factors beyond the typical clinical-stage biotech profile. Combined with a long timeline to the Phase 2b data readout and no approved products or material revenue, this contributed to a sustained reduction in the stock's valuation. The October cost-cutting measures, while designed to improve the balance sheet outlook, reinforced the perception of a constrained cash position and accelerated the downward trend.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a broader universe of hundreds of bots trading thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving visitors a focused view of strategies that are currently attracting attention. The bots vary widely in trading strategy, timeframe, and performance metrics, so investors can evaluate approaches that align with their own objectives. For those interested in data-driven, automated trading tools, exploring the Trending AI Robots section offers a practical way to see how AI is being applied across the market.
ENLV Stock Forecast Drivers: What Investors Should Watch Next
The most important catalyst ahead is the Phase 2b Allocetra trial in knee osteoarthritis. Management expects topline six-month data by mid-2027, and enrollment progress, trial updates, and the eventual readout will likely be the primary drivers of the stock. Positive results could validate the program's disease-modifying potential in an indication with no currently approved disease-modifying therapies, while a negative or ambiguous outcome would materially shift the risk profile.
Investors should also monitor the company's cash position and any financing activity, given the pre-revenue profile and the extended timeline to the data readout. Regulatory milestones related to the RMAT designation, competitive developments in the osteoarthritis space, and the performance of the company's prediction markets treasury are additional factors worth watching. These are forward-looking considerations, not investment advice or predictions of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ENLV in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 30, 2026
ENLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 35 cases where ENLV's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +9.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENLV advanced for three days, in 158 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ENLV entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.006) is normal, around the industry mean (3.498). P/E Ratio (0.001) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions
Industry Biotechnology